ライフサイエンスコーパス: healthy control subject

1 diagnostic studies (572 CHR patients and 480 healthy control subjects).

2 ion carriers, and 82 demographically matched healthy control subjects.

3 um cells from nine subjects with CF and five healthy control subjects.

4 eakness compared to neurological disease and healthy control subjects.

5 patients with a range of MDD duration and 83 healthy control subjects.

6 There was no effect in healthy control subjects.

7 e Severe Asthma Research Program-3 and in 94 healthy control subjects.

8 us parents and within the range noted in six healthy control subjects.

9 -A, and STC2 on day 0 and 7 were compared to healthy control subjects.

10 istidine levels compared with 10 age-matched healthy control subjects.

11 nt topologies between asthmatic patients and healthy control subjects.

12 inocytes distinguished patients with LN from healthy control subjects.

13 %, P = .003; tCho/mI: -18%; P = .04) than in healthy control subjects.

14 with schizophrenia spectrum disorders and 30 healthy control subjects.

15 sma of patients with DM and DN compared with healthy control subjects.

16 t of 71 patients and 68 age- and sex-matched healthy control subjects.

17 cortical grey and white matter segments than healthy control subjects.

18 19 age-, sex- and educational level-matched healthy control subjects.

19 d, moderate, and severe asthma and nonatopic healthy control subjects.

20 e loop in chronic schizophrenia patients and healthy control subjects.

21 ated, mild-to-moderate disease compared with healthy control subjects.

22 ents with Gram-negative sepsis compared with healthy control subjects.

23 els for total cell-free circulating RNA from healthy control subjects.

24 patients with ET and 18 age- and sex-matched healthy control subjects.

25 man serum samples from lymphoma patients and healthy control subjects.

26 hronic schizophrenia patients and 26 matched healthy control subjects.

27 acteria and less Bacteroidetes compared with healthy control subjects.

28 of patients with CVID compared with those of healthy control subjects.

29 te allergens in DOCK8-deficient patients and healthy control subjects.

30 as a higher prevalence of LGE compared with healthy control subjects.

31 striatum in 13 pathological gamblers and 15 healthy control subjects.

32 from patients with mild-to-severe asthma and healthy control subjects.

33 urological memory-disordered patients and 14 healthy control subjects.

34 splay methylation levels similar to those of healthy control subjects.

35 unced evidence of inflammation compared with healthy control subjects.

36 26 with bipolar disorder) and 50 age-matched healthy control subjects.

37 re strongly connected to one another than in healthy control subjects.

38 sample of 20 patients with IS and 20 matched healthy control subjects.

39 did not differ between patients with FEP and healthy control subjects.

40 as not significantly different compared with healthy control subjects.

41 al temporal pole were found in NTSCUs versus healthy control subjects.

42 g of serotonin transporter (SERT) density in healthy control subjects.

43 study of 87 participants with morphea and 26 healthy control subjects.

44 y had metabolic profiles similar to those of healthy control subjects.

45 ed and miglustat treated), heterozygote, and healthy control subjects.

46 ptomic differences compared neutrophils from healthy control subjects.

47 nts (at 12-month intervals) from 147 UHR and healthy control subjects.

48 eased in pathological gamblers compared with healthy control subjects.

49 n the cortical regions in CDSs compared with healthy control subjects.

50 stic fibrosis patients compared with that of healthy control subjects.

51 CD55 was seen less in patients compared with healthy control subjects.

52 of at least moderate severity and 13 matched healthy control subjects.

53 ral blood of allergic asthmatic patients and healthy control subjects.

54 ter in patients with prostate cancer than in healthy control subjects.

55 -free nonsmoking patients with asthma and 10 healthy control subjects.

56 mmatory cells in severe asthma compared with healthy control subjects.

57 f severe child abuse, and of psychiatrically healthy control subjects.

58 BD) exempt of Parkinsonian signs compared to healthy control subjects.

59 complexity were analyzed and compared to 26 healthy control subjects.

60 ned from patients with GPP, PPP, or AGEP and healthy control subjects.

61 asthmatic patients with more eosinophils and healthy control subjects.

62 the opposite was observed in abstainers and healthy control subjects.

63 surements in patients with heart failure and healthy control subjects.

64 ith first-episode psychosis as compared with healthy control subjects.

65 l caudate of patients with FEP compared with healthy control subjects.

66 ion in steroid-free patients with asthma and healthy control subjects.

67 out chronic erythromycin administration, and healthy control subjects.

68 al valve surgery and 13 age- and sex-matched healthy control subjects.

69 were 7,048 leprosy patients and 14,398 were healthy control subjects.

70 n patients with major depression relative to healthy control subjects.

71 aries derived from 11 MG patients and paired healthy control subjects.

72 pus erythematosus without past NPSLE, and 19 healthy control subjects.

73 ) levels in asthmatic patients compared with healthy control subjects.

74 ar composition in schizophrenia patients and healthy control subjects.

75 t in patients with IBD compared with that in healthy control subjects.

76 venous hydrocortisone challenge (CORT) in 19 healthy control subjects.

77 sive disorder who switched medication and 38 healthy control subjects.

78 nction in patients with schizophrenia and in healthy control subjects.

79 tion that do not differ between patients and healthy control subjects.

80 patients with first-episode psychosis and 20 healthy control subjects.

81 ead and macula was conducted in patients and healthy control subjects.

82 moglobin from 18 oral cancer patients and 15 healthy control subjects.

83 ally proven Fabry disease and 19 age-matched healthy control subjects.

84 ss and higher negative valence compared with healthy control subjects.

85 th acute ischaemic stroke and 17 age-matched healthy control subjects.

86 oderate-severe traumatic brain injury and 19 healthy control subjects.

87 gnosed in 2013-2014 were included along with healthy control subjects.

88 patients and age-, race-, and gender-matched healthy control subjects.

89 ance that differed from correlations seen in healthy control subjects.

90 compared to Parkinson's disease patients and healthy control subjects.

91 ncreased in asthmatic patients compared with healthy control subjects.

92 imp-1 expression compared with expression in healthy control subjects.

93 llowing mild-repetitive or severe TBI and 15 healthy control subjects.

94 etween individuals with major depression and healthy control subjects.

95 study participants with ALS as compared with healthy control subjects.

96 nocyte-derived macrophages (MDM) in COPD and healthy control subjects.

97 king CD71 in patients with IPF compared with healthy control subjects.

98 CD71 in the BAL of patients with IPF and of healthy control subjects.

99 with Sacin-high asthma compared with that in healthy control subjects (0.024 vs 0.017, P < .05).

100 ge, 22 years) and 36 normotensive previously healthy control subjects (14 men; median age, 43 years;

101 nificantly thinner in glaucoma patients than healthy control subjects (141.7 +/- 66.3 mum vs 155.7 +/

102 ith those in patients with venom allergy and healthy control subjects (21 and 23.4 cells/muL, P < .00

103 ly myopic patients (46 eyes), 11 age-matched healthy control subjects (21 eyes), and 34 patients (66

104 1.3% +/- 2.8 vs 28.2% +/- 3.4, P = .030) and healthy control subjects (27.0% +/- 3.1, P = .003).

105 In 126 adults (33 healthy control subjects, 31 patients with mild asthma,

106 rare but more common in pNF subjects than in healthy control subjects (4 versus 1).

107 ts (47 +/- 15 years of age, 77% male) and 30 healthy control subjects (46 +/- 16 years of age, 70% ma

108 2M) with chronic low back pain (cLBP) and 27 healthy control subjects (48.9 +/- 13 years old; 14F, 13

109 ndard deviation]; 10 men) and 11 age-matched healthy control subjects (54 years +/- 15; eight men) un

110 of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for I

111 n; mean age, 39 years +/- 11) along with 147 healthy control subjects (97 women; mean age, 42 years +

112 oduced significantly more IL-6 compared with healthy control subjects after exposure to toll-like rec

113 ts) before and 42 patients (compared with 52 healthy control subjects) after an exposure-based CBT.

114 533 individuals with 22q11DS and 330 matched healthy control subjects (age range, 6-56 years; 49% fem

115 Fifteen healthy control subjects also underwent neuromelanin-sen

116 on (b = .056, p = .035) in both patients and healthy control subjects, although the association with

117 A total of 28 MIS-C, 20 healthy control subjects and 20 classic Kawasaki disease

118 Results The study included 96 healthy control subjects and 332 participants with MS (i

119 anodal, cathodal and sham stimulation to 24 healthy control subjects and 35 patients with moderate/s

120 We recruited 80 healthy control subjects and AD patients with and withou

121 atment-seeking cocaine users (NTSCUs) and 67 healthy control subjects and an independent treatment-co

122 MCs were isolated from patients with PAH and healthy control subjects and assessed for expression of

123 ents with neurodegenerative disease and 4351 healthy control subjects and found p.A152T associated wi

124 ated plasma exosomes from 23 patients and 11 healthy control subjects and found significantly higher

125 No significant difference was found between healthy control subjects and glaucoma patients in the me

126 (27.9%), and these subjects were older than healthy control subjects and had higher triglycerides, l

127 icantly reduced in MS patients compared with healthy control subjects and other inflammatory neurolog

128 e differentiation and monocyte activation in healthy control subjects and patients with autoinflammat

129 epithelial cells (PBECs) were isolated from healthy control subjects and patients with COPD and infe

130 72 hours in PBECs; this was similar between healthy control subjects and patients with COPD.

131 5b-5p, and miR-143-3p differentiated between healthy control subjects and patients with IS with an ar

132 th painful diabetic neuropathy compared with healthy control subjects and patients with painless diab

133 differentiate patients with PD and MCI from healthy control subjects and patients with PD without MC

134 s and subcortical volume differences between healthy control subjects and psychiatric patients from 1

135 ulate cortex in the developers compared with healthy control subjects and recoverers.

136 k allergy is increased compared with that in healthy control subjects and that the intensity of expre

137 more errors on the masked priming task than healthy control subjects and the types of errors were co

138 ects with atopy but no asthma, and nonatopic healthy control subjects and to determine relationships

139 omes from 15 patients with sarcoidosis and 5 healthy control subjects and verified the most interesti

140 gram [GSK-HiTDiP] study (113 patients and 57 healthy control subjects) and the Janssen-Brain Resource

141 ols), replication (200 patients with IS, 100 healthy control subjects), and in 72 patients with trans

142 opsy specimens (91 asthmatic patients and 46 healthy control subjects), and whole blood samples (n =

143 To this end, 40 MS patients, 30 healthy control subjects, and 30 patients with other inf

144 gy have distinct gut microbiomes compared to healthy control subjects, and dysbiosis precedes the dev

145 tial OPN targets in biopsies of HF patients, healthy control subjects, and human induced pluripotent

146 s had intermediate enlargement compared with healthy control subjects; and total choroid plexus volum

147 Nasal secretions were collected from healthy control subjects, AR patients, and idiopathic rh

148 to 6 times higher in patients with AD versus healthy control subjects at 3 months of age (odds ratio,

149 tified 27 children with atopic wheeze and 70 healthy control subjects at 5 years of age.

150 subset of 20 early-psychosis patients and 31 healthy control subjects, baseline hippocampal activity

151 ients with panic disorder (compared with 150 healthy control subjects) before and 42 patients (compar

152 ith Trail-Making Test, Part B, time spent in healthy control subjects but not in chronic schizophreni

153 triatum predicted worse cognitive control in healthy control subjects but not in chronic schizophreni

154 en people with major depressive disorder and healthy control subjects, but few studies have specifica

155 with T2-low asthma were differentiated from healthy control subjects by lower expression of a cytoto

156 with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resolution posit

157 ts with first-episode psychosis (FEP) and 18 healthy control subjects completed the study.

158 bronchial brushings were also obtained from healthy control subjects comprising of adolescents admit

159 fferences between vulnerable individuals and healthy control subjects could help identify those at hi

160 Healthy control subjects displayed a conventional decrea

161 rs studied 66 schizophrenia patients and 143 healthy control subjects during performance of context u

162 up) with differing insulinemia and glycemia: healthy control subjects (euinsulinemia and euglycemia),

163 ant improvements in depressive symptoms, and healthy control subjects exhibited modest but significan

164 etween patients with psychotic disorders and healthy control subjects (F(1,62.85) = 0.48, p = .49).

165 ands compared with first-degree relatives or healthy control subjects; first-degree relatives had int

166 ediates in subjects with type 1 diabetes and healthy control subjects followed for 3 years.

167 134 patients with Hymenoptera allergy and 76 healthy control subjects for comparison.

168 tional limb weakness, 46 neurological and 38 healthy control subjects from our previously studied pro

169 data and biospecimens from 909 AA and 847 EA healthy control subjects from the Carolina Breast Cancer

170 eight neurological control subjects and one healthy control subject had died.

171 ubjects had 11C-Pittsburgh compound B and 10 healthy control subjects had 11C-(R)-PK11195 positron em

172 Twelve age-matched healthy control subjects had 11C-Pittsburgh compound B a

173 Medication-free patients with MDD and healthy control subjects (HC) completed baseline rs-fcMR

174 from studies comparing patients with OCD and healthy control subjects (HCs) during error processing a

175 -four patients with LLD and 27 non-depressed healthy control subjects (HCs) of comparable age, sex, a

176 ubjects with schizophrenia (SCH) relative to healthy control subjects (HCs).

177 ources more narrowly but more intensely than healthy control subjects (HCS).

178 urately differentiate patients with MDD from healthy control subjects (HCs).

179 ources more intensely but more narrowly than healthy control subjects (HCS).

180 without polyneuropathy (nDPN)-along with 30 healthy control subjects (HCs).

181 nate patients with schizophrenia (SCZs) from healthy control subjects (HCs).

182 ated by APS-IgG and SLE/APS- IgG compared to healthy control subjects' IgG, and FXa alone.

183 encing was performed for all index cases and healthy control subjects in a central laboratory.

184 h biallelic PRKN/PINK1 mutations compared to healthy control subjects in a German cohort, supporting

185 difference between pathological gamblers and healthy control subjects in terms of dopamine transmissi

186 expression from 155 subjects with asthma and healthy control subjects in the Severe Asthma Research P

187 lated in patients with EA+EoE- compared with healthy control subjects, including those involved in ep

188 Differences between patients with MDD and healthy control subjects increased with progressively re

189 In schizophrenia patients relative to healthy control subjects, increased activations were obs

190 endent humans as identified by DSM-IV and 15 healthy control subjects matched for age, sex, and smoki

191 individuals with cocaine use disorder and 26 healthy control subjects matched for age, sex, and smoki

192 er instability were investigated in 33 young healthy control subjects (mean age +/- standard deviatio

193 ashlight method (mean age 49.6 years) and 50 healthy control subjects (mean age 31.3 years) were exam

194 10 [standard deviation], eight women) and 30 healthy control subjects (mean age, 50 years +/- 10; 16

195 d deviation]) were compared with those in 10 healthy control subjects (mean age, 50.3 years +/- 17.2)

196 tandard deviation, 31 years +/- 5), 34 older healthy control subjects (mean age, 67 years +/- 8), 34

197 e=14.76 years [SD=2.00], 68% female) and 187 healthy control subjects (mean age=14.67 years [SD=2.45]

198 atients showed significantly higher RVI than healthy control subjects (mean=0.18 [SD=0.03] and mean=0

199 For CSPG4Es of 24 healthy control subjects, mean levels of hepatocyte grow

200 -3 (Severe Asthma Research Program-3) and 79 healthy control subjects.Measurements and Main Results:

201 e, 51 years; range, 30-68 years) and 11 male healthy control subjects (median age, 45 years; range, 3

202 nosis of different causes in comparison with healthy control subjects.Methods: During the last two de

203 gnosed SDB warranting adenotonsillectomy and healthy control subjects.Methods: Thirty children who ha

204 lated in patients with IS compared with both healthy control subjects (miR-125a-5p [1.8-fold; P=1.5x1

205 ophils from blood and airway secretions from healthy control subjects (n = 12), PWCF (n = 16), and PW

206 ton syndrome, n = 4), as well as age-matched healthy control subjects (n = 14), patients with psorias

207 n, and compared their performance to matched healthy control subjects (n = 18), in behavioural tasks

208 th generalized anxiety disorder (n = 24) and healthy control subjects (n = 20), patients with post-tr

209 th pathological anxiety (n = 25) and matched healthy control subjects (n = 23) completed a gambling t

210 ders without CU traits (CD/CU-; n = 25), and healthy control subjects (n = 24).

211 ecurrent depression patients (n = 36) versus healthy control subjects (n = 27).

212 = 30) and macroalbuminuria (n = 30), and in healthy control subjects (n = 30).

213 rest in recently abstinent CDSs (n = 24) and healthy control subjects (n = 36) both before and after

214 ith persistent atopic asthma (n = 36) versus healthy control subjects (n = 36).

215 nd classified into four clinical groups: RV- healthy control subjects (n = 37), RV+ asymptomatic subj

216 ither sex with varying degrees of psychosis: healthy control subjects (n = 46), schizophrenia patient

217 ent (n = 1062) or remitted (n = 711) MDD and healthy control subjects (n = 497).

218 am, sertraline, or venlafaxine (8 weeks) and healthy control subjects (n = 59; age 18-65 years).

219 ewly diagnosed type 1 diabetes (n = 654) and healthy control subjects (n = 605) were analyzed in radi

220 ease ~10 weeks after infection (n = 109) and healthy control subjects (n = 98).

221 ith idiopathic or heritable PAH (n=365) from healthy control subjects (n=121) after correction for mu

222 ofile (n=38), MCI with AD profile (n=20) and healthy control subjects (n=20).

223 child abuse, as well as from psychiatrically healthy control subjects (N=26).

224 ural T(1)-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients wit

225 lammatory response in monocytes derived from healthy control subjects (n=6).

226 were treatment resistant (N=37), as well as healthy control subjects (N=78; mean age, 39.2 years).

227 hizophrenia, N=51; psychosis risk, N=39; and healthy control subjects, N=53), the authors conducted a

228 ts without DPN (eight men, 12 women), and 20 healthy control subjects (nine men, 11 women).

229 Patients with HFpEF and healthy control subjects of similar age and sex distribu

230 in portopulmonary hypertension (PoPH) versus healthy control subjects, or other etiologies of PAH or

231 -degree and axis II cluster A relatives, and healthy control subjects, organized by DSM-IV-TR diagnos

232 ith mastocytosis had lower FMD compared with healthy control subjects (P < .001).

233 n patients with mitral regurgitation than in healthy control subjects (P < .001).

234 diabetic patients without DPN (P < .001) and healthy control subjects (P < .001).

235 ents with AUD and 43 demographically matched healthy control subjects participated in the fMRI experi

236 Relative to healthy control subjects, pathologically anxious partici

237 RT-PCR and compared them with specimens from healthy control subjects, patients with atopic dermatiti

238 Ago-2 fractions isolated from EDTA plasma of healthy control subjects, patients with diabetes mellitu

239 ective study identified 4 EoE study cohorts: healthy control subjects, patients with EA and EoE (EA+E

240 ne mean [T2GM]) in induced sputum cells from healthy control subjects, patients with severe asthma re

241 Participants were categorized as healthy control subjects (reported no DEB at both time p

242 ces often observed between cocaine users and healthy control subjects result from a history of drug u

243 (mean deviation between 0 and - 6 dB) and 68 healthy control subjects selected by Propensity Score Ma

244 Finally, healthy control subjects showed an inverse relationship

245 We demonstrated in younger healthy control subjects that this promotes a switch to

246 gene expression and regulation, relative to healthy control subjects, that may influence systemic im

247 lts showed that in patients, compared to the healthy control subjects, the volume of the substantia n

248 ertoire shifted from alveolar macrophages in healthy control subjects to a predominance of recruited

249 e patients with Alzheimer's disease and five healthy control subjects to analyse the presence of phos

250 le sclerosis participants and 11 age-matched healthy control subjects to undergo 7 T imaging of the c

251 two patients with Parkinson's disease and 14 healthy control subjects underwent 3 T MRI and a 120-min

252 patients with relapsing-remitting MS and 20 healthy control subjects underwent a 3-T resting-state f

253 Forty-four patients with epilepsy and 16 healthy control subjects underwent an electroencephalogr

254 d-positive mild cognitive impairment) and 29 healthy control subjects underwent baseline assessment w

255 mmol/mol [9.1 +/- 1.8%]) and 48 age-matched healthy control subjects underwent CCM.

256 s, n = 14, and nonresponders, n = 15) and 26 healthy control subjects underwent detailed sensory prof

257 patients with relapsing-remitting MS and six healthy control subjects underwent diffusion-weighted im

258 h schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance sp

259 ts with newly diagnosed, untreated MM and 16 healthy control subjects underwent spinal MR imaging inc

260 even patients with asthma and 17 age-matched healthy control subjects underwent spirometry, body plet

261 Patients with stable asthma and healthy control subjects underwent spirometry, methachol

262 lacement therapy, along with 50 age-matched, healthy control subjects using resting state functional

263 from patients with lupus nephritis and from healthy control subjects using single-cell RNA sequencin

264 nal samples and 5 nonlesional samples) and 7 healthy control subjects, using 10x Genomics.

265 tients with functional gait disorders and 17 healthy control subjects walked onto a stationary sled (

266 ood from patients with atopic dermatitis and healthy control subjects was analyzed with flow cytometr

267 Reduced cortical glutamine relative to healthy control subjects was observed in patients with s

268 ith PD (54 with MCI, 116 without MCI) and 41 healthy control subjects was obtained by using determini

269 ion data from 84 subjects with asthma and 27 healthy control subjects was used to identify immune cel

270 [(11)C]NOP-1A data from 18 healthy control subjects were also included to provide a

271 h current depressive symptoms and 10 matched healthy control subjects were analyzed as well.

272 osis patients and 35 demographically matched healthy control subjects were analyzed using a block-des

273 eyes with PXS, 84 eyes with PXG, and 44 eyes healthy control subjects were analyzed.

274 2D (HbA1c >7.5%) and 24 age- and sex-matched healthy control subjects were consecutively enrolled.

275 a confirmed diagnosis of CF and age-matched healthy control subjects were enrolled at three North Am

276 nt and advanced forms of mastocytosis and 20 healthy control subjects were enrolled in the study.

277 e functional connectivity between NTSCUs and healthy control subjects were identified.

278 images from 453 patients with NIDCM and 150 healthy control subjects were included between 2005 and

279 n CCF and 19 eyes of 19 age- and sex-matched healthy control subjects were included.

280 supranuclear palsy-frontal subtypes) and 20 healthy control subjects were included.

281 67/2005 (H3N2) by intranasal inoculation; 35 healthy control subjects were not subjected to the viral

282 21 subjects with atopy but no asthma, and 21 healthy control subjects were profiled by using 16S rRNA

283 a in study participants with chronic SCI and healthy control subjects were prospectively acquired in

284 Twenty-eight patients with CSM and 10 healthy control subjects were prospectively recruited an

285 ore pronounced autistic traits in a group of healthy control subjects were related to lower scores as

286 Nonlesional skin of patients with AD and healthy control subjects were sampled at 2 time points s

287 Healthy control subjects were studied under normoglycemi

288 imer's disease and 16 (age- and sex-matched) healthy control subjects were studied using Actiheart de

289 n = 9), mild asthma patients (n = 7), and 10 healthy control subjects were studied.

290 Sera of 1062 patients with CSU and 482 healthy control subjects were used in an IgE-anti-IL-24-

291 was performed in 263 CHR individuals and 51 healthy control subjects, who were then clinically monit

292 CHR patients could be classified against healthy control subjects with 78% sensitivity and 77% sp

293 ed a sample of 120 patients with BPD and 115 healthy control subjects with a well-established functio

294 rst-episode psychosis as well as age-matched healthy control subjects with magnetic resonance spectro

295 Compared with the healthy controls, subjects with MetS had significantly r

296 tions in functional importance (r = -0.23 in healthy control subjects), with an almost complete loss

297 and chronic schizophrenia (SCZ) compared to healthy control subjects, with even lower activity in tr

298 .1 [95% CI, 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 14

299 S patients without encephalopathy, and to 15 healthy control subjects without CMS.

300 1c) 7.1 +/- 0.7% [54 +/- 7 mmol/mol]) and 11 healthy control subjects without diabetes (HbA(1c) 5.5 +